<code id='38E0AA4CC2'></code><style id='38E0AA4CC2'></style>
    • <acronym id='38E0AA4CC2'></acronym>
      <center id='38E0AA4CC2'><center id='38E0AA4CC2'><tfoot id='38E0AA4CC2'></tfoot></center><abbr id='38E0AA4CC2'><dir id='38E0AA4CC2'><tfoot id='38E0AA4CC2'></tfoot><noframes id='38E0AA4CC2'>

    • <optgroup id='38E0AA4CC2'><strike id='38E0AA4CC2'><sup id='38E0AA4CC2'></sup></strike><code id='38E0AA4CC2'></code></optgroup>
        1. <b id='38E0AA4CC2'><label id='38E0AA4CC2'><select id='38E0AA4CC2'><dt id='38E0AA4CC2'><span id='38E0AA4CC2'></span></dt></select></label></b><u id='38E0AA4CC2'></u>
          <i id='38E0AA4CC2'><strike id='38E0AA4CC2'><tt id='38E0AA4CC2'><pre id='38E0AA4CC2'></pre></tt></strike></i>

          
          WSS
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge